Company: BIVIW
Filing Date: 2025-08-08
Form Type: 424B5
Source: 0001520138-25-000247
Chunk: 72

Company: BIOVIE INC.
Filing Date: 2025-08-08
Form: 424B5
Chunk 72
---
 | the absence of liquidity in our Common Stock; |

| - | the risk of substantial dilution from future issuances of our equity securities; and |

| - | the other risks set forth herein under the caption “Risk Factors.” |

<div align='center'>35</div>

The foregoing does not represent an exhaustive
list of matters that may be covered by the forward-looking statements contained herein or risk factors that we are faced with. The factors
set forth above under “Risk Factors” and other cautionary statements made in this prospectus should be read and understood
as being applicable to all related forward-looking statements wherever they appear in this prospectus. The forward-looking statements
contained in this prospectus represent our judgment as of the date of this prospectus. We caution readers not to place undue reliance
on such statements. You should read this prospectus and the documents that we have filed as exhibits to this prospectus completely and
with the understanding that our actual future results may be materially different from the plans, intentions and expectations disclosed
in the forward-looking statements we make. Except as required by law, we undertake no obligation to update publicly any forward-looking
statements for any reason, even if new information becomes available or other events occur in the future. All subsequent written and oral
forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary
statements contained above and throughout this prospectus.

<div align='center'>36

Use of Proceeds</div>

We estimate that the net proceeds from this offering will be approximately $10.7 million, or approximately $12.4 million if the underwriters exercise their over-allotment option to purchase additional shares of Common Stock in full, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.

We intend to use the net proceeds from this offering for working capital
and general corporate purposes. This may include, but is not limited to, capital expenditures, research and development expenditures and
acquisitions of new technologies or businesses.

Although we have identified some potential uses
of the net proceeds to be received from this offering, we cannot specify these uses with certainty. The allocations of the proceeds of
this offering presented above constitute the current estimates of our management and are based on our current plans, assumptions made
with respect to the industry in which we currently or, in the future, expect to operate, general economic conditions and our future revenue
and expenditure estimates. Our management will have broad discretion in the application of